DAPA Contract

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura plc

("Belluscura" or the "Company" or "Group")

Belluscura is awarded a Distribution and Pricing Agreement ("DAPA") from the United States Defense Logistics Agency ("DLA") for the X-PLOR

LONDON, U.K. AND PLANO, TX, U.S. (7 April 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the X-PLOR portable oxygen concentrator has been awarded a Distribution and Pricing Agreement ("DAPA") code from the U.S. Defense Logistics Agency ("DLA") through our distribution partner, Lovell Government Services Inc ("Lovell"). DLA procures items from manufacturers and suppliers and provides them to the Department of Defense and other federal/state customers throughout the US and globally. DLA procures more than $41.8 billion in goods and services annually on behalf of its customers.

Lovell is a Service-Disabled Veteran-Owned military purchasing organisation Small Business whose primary mission is to provide exclusive medical, surgical, and pharmaceutical resources to the U.S. Department of Defense and Veterans Affairs Medical Organizations. Lovell has already commenced selling the X-PLOR.

Robert Rauker, Chief Executive Officer, Belluscura plc, commented: "Receiving the DAPA code opens up a significant sales opportunity for the X-PLOR as it is now available through the DLA system which includes the military installations, military hospitals and other federal and state agencies serviced by the DLA."

Chris Lovell Major USMC Retired, Chief Executive Officer, commented: "We are delighted to be working with Belluscura and its advanced oxygen products. The United States government is the largest buyer in the world." 

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.